Nicotine is the primary addictive component of tobacco products and its complex stimulus effects are readily discriminated by human and non-human animals. Previous research with rodents directly investigating the nature of the nicotine stimulus has been limited to males. The current study began to address this significant gap in the literature by training female and male rats to discriminate 0.4 mg/kg nicotine from saline in the discriminated goal-tracking task. In this task, access to sucrose was intermittently available on nicotine session. On interspersed saline session, sucrose was not available. Both sexes acquired the discrimination as evidenced by increased head entries into sucrose receptacle (goaltracking) evoked by nicotine; the nicotine generalization curves were also similar between females and males. The pharmacological profile of the nicotine stimulus was assessed using substitution and targeted combination tests with the following ligands: sazetidine-A, PHA-543613, PNU-120596, bupropion, nornicotine, and cytisine. For females and males, nornicotine fully substituted for the nicotine stimulus, whereas sazetidine-A, bupropion, and cytisine all evoked partial substitution. Female and male rats responded in a similar manner to interaction tests where a combination of 1 mg/kg of sazetidine-A plus nicotine or nornicotine shifted the nicotine dose-effect curve to the left. The combination of sazetidine-A plus bupropion or cytisine failed to do so. These findings begin to fill a significant gap the in scientific literature by studying the nature of the nicotine stimulus and response to therapeutically interesting combinations using a model that includes both sexes.
Introduction
Smoking is the leading preventable cause of death in the United States, responsible for approximately 443,000 deaths annually (CDC, 2008) . In spite of well-known health risks, nearly 70 million Americans continue to use tobacco products (NIDA, 2012) . Most smokers, almost 70%, report that they desire to quit smoking (CDC, 2011) . Gender can play an important role in this tenacious addiction, as well as in the success of smoking cessation treatments. Though fewer women smoke than men, the quit attempts of women are less likely to be successful compared to male counterparts, and there is increased sensitivity to social and behavioral factors related to tobacco use among women [for reviews see Perkins (2008) and Schnoll et al. (2007) ]. There is no doubt that socio-environmental factors are likely the cause of some of these sex differences. However, the potential import of biological factors cannot be ignored (Arnold, 2009; Beery and Zucker, 2011; Cahill, 2006; Wetherington, 2007) . These include the widespread effect of gonadal hormones early in development on the organization of the physiology including the nervous system, the differential impact of circulating gonadal hormones that vary across the lifespan of the individual, and the differential expression of X and Y genes in women and men (i.e., sex chromosome effects).
Preclinical models with rodents have also identified sex differences in the effects of nicotine further suggesting a biological mechanism for at least some of the differences. For example, females were more sensitive than males to the acute locomotor effects of nicotine (Harrod et al., 2004; Kanýt et al., 1999) . This sex difference in the stimulant effects of nicotine was reduced in gonadectomized females (Booze et al., 1999; Kanýt et al., 1999) . Further, female rats have higher rates of nicotine selfadministration in comparison to males (Donny et al., 2000) . Adult female rats also appear to be more sensitive to the rewardenhancing effects of nicotine and they will take more nicotine than males when a weak sensory reinforcer also follows lever pressing (Chaudhri et al., 2005) . Consistent with this observation, in a place conditioning tasks, adult female rats were more sensitive than male rats to the conditioned rewarding effects of nicotine; evidence of conditioned reward was abolished in ovariectomized females (Torres et al., 2009) . In the present study, we sought to extend the work on sex differences by investigating whether the nature of the nicotine stimulus differed between female and male rats.
Over the years, a variety of tasks have been developed to study the interoceptive stimulus effects of drugs in rodents and primates (Murray et al., 2011; Stolerman et al., 2009; Wooters et al., 2009 ). These drug discrimination tasks have served as powerful tools for understanding the behavioral and neuropharmacological processes of psychoactive substances. For the present study, we used the drug discriminated goal-tracking (DGT) task (Besheer et al., 2004) to study the interoceptive stimulus effects of nicotine. In the DGT task, rats have intermittent access to non-contingent liquid sucrose deliveries when given nicotine before the session. On intermixed saline sessions, sucrose is not available. A discrimination between nicotine and saline develops as evidenced by nicotine differentially evoking goal-tracking [i.e., "anticipatory" head entries into the site where sucrose was delivered; see Boakes (1977) and Farwell and Ayres (1979) ]. This discrimination is specific to the pharmacological effect of nicotine and does not reflect a drug vs no drug discrimination (Besheer et al., 2004; ).
Sex differences involving interoceptive conditioning with the nicotine stimulus have not been studied in the DGT task. Further, after an extensive search of the two-lever drug discrimination literature (cf. Stolerman et al., 2009; Wooters et al., 2009 ), we could not find a published paper with rodents that used nicotine as the training stimulus and examined potential sex differences (cf. Bevins and Charntikov, 2015) . The only published sex difference involving the nicotine stimulus in rodents that we found was that reported in Jung et al. (2000) . In that report, male and female rats were trained to discriminate pentylenetetrazol from saline. In substitution tests, nicotine prompted less pentylenetetrazol-like responding in females than males. Albeit limited, this outcome, combined with the work from Perkins and colleagues in humans (Perkins, 1999; Perkins et al., 1996) , indicates the need to better understand the nature of the nicotine stimulus in both sexes. With this need in mind, the goal of the present study was to begin to fill this gap in the scientific literature on nicotine drug discrimination. Table 1 lists the ligands we used to better understand the nature of the nicotine stimulus in female and male rats, as well as the purported mechanism(s) of each ligand. The ligands were selected because of their action on nicotinic acetylcholine receptors [nAChR (e.g., sazetidine-A)] and/or their use in smoking cessation (e.g., bupropion). As detailed in the Methods section, we investigated the substitution pattern of bupropion, cytisine, nornicotine, sazetidine-A, PNU-120596, and PHA-543613 in the DGT task. Based on the results of our substitution tests, we used interaction tests to further inform us about pharmacological profile of selected nicotine-like ligands. Because there is a significant gap in understanding pharmacology associated with sazetidine-A's nicotine-like stimulus effect, we focused our interaction tests on combinations including sazetidine-A with nicotine, bupropion, nornicotine, or cytisine. Interaction tests were also used to test the effect of PNU-120596, a positive allosteric modulator for the a7 subunit of nicotinic acetylcholine receptors, in a condition of elevated cholinergic tone induced by a low nicotine dose.
Materials and Methods

Animals
Subjects were young adult male (n ¼ 24) and female (n ¼ 24) Sprague-Dawley rats from Harlan Laboratories (Indianapolis, IN, USA). Males weighed 271e312 g and females weighed 206e230 g upon arrival. Rats were divided and tested consecutively in two equal sets; 12 rats of each sex per replication. They were individually housed in clear polycarbonate cages (48.3 Â 26.7 Â 20.3 cm) lined with TEKFresh ® cellulose bedding (Harlan Laboratories). The colony room was on a 12 h light:dark schedule; lights on at 0600. All experiments were conducted during the light cycle. Water was freely available in the home cage. Access to chow (Harlan Teklad Diet, Harlan Laboratories, KY, USA) was restricted to maintain rats at 85% of free-feeding body weight. This 85% target was determined by sampling free-feed weight for three days after a week of acclimation to our colony. This 85% target weight was increased by 2 g every 4 weeks. Rats were handled for at least 2 min during the 3 days before the start of the experiment. All protocols were approved by the University of Nebraska-Lincoln Institutional Animal Care and Use Committee.
Apparatus
Behavioral testing was conducted in commercially available chambers (ENV-008CT, Med Associates, St. Albans, VT, USA) measuring 30.5 Â 24.1 Â 21.0 cm (l Â w Â h). Each chamber was enclosed in a sound-and light-attenuating cubicle equipped with an exhaust fan. Each conditioning chamber was constructed of aluminum sidewalls, polycarbonate front, back, and ceiling, with a floors constructed of metal rods. A recessed receptacle (5.2 Â 5.2 Â 3.8 cm; l Â w Â d) was centered on one of the sidewalls. The receptacle had a dipper arm, when raised, provided access to 0.1 ml of 26% (w/v) sucrose solution. Dipper access was monitored by an infrared beam placed 1.2 cm into the receptacle and 3 cm above the chamber floor. A second infrared beam that monitored chamber activity was located 4 cm above the floor and 14.5 cm from the side wall containing the receptacle. Experimental session and collection of beam breaks were controlled using Med Associates interface and software (Med-PC for Windows, version IV). 
Drugs
Behavioral procedures
Discrimination Training. Rats were injected with nicotine (0.4 mg/kg, subcutaneous [SC] ) in the home cage for 3 consecutive days before discrimination training commenced to reduce the initial locomotor-suppressant effects of nicotine (Besheer et al., 2004; Bevins et al., 2001) . In each of 32 daily training sessions, rats were administered nicotine or saline 5 min before placement in the chamber for the 20-min session. Rats received a pseudorandom order of 16 nicotine and 16 saline sessions with the condition that no more than two of the same session type (nicotine vs. saline) occurred in a row. On nicotine sessions, there were 36 deliveries of sucrose with each access limited to 4 s. The first sucrose delivery occurred between 124 and 152 s from the start of the session with 4 possible start times pseudorandomized throughout the training phase. Time between subsequent sucrose deliveries ranged from 4 to 80 s (mean ¼ 25 s). For intermixed saline sessions, sucrose was withheld. Discrimination training, and all remaining phase, was conducted in a dark chamber. On one of the training days, two females and ten males had an inappropriate program executed during training (i.e., saline day instead of nicotine, or vice versa). These rats had 3 extra nicotine and 3 extra saline sessions. To estimate the missing value for each rat for graphing and analyses, the average of the day preceding and the day following the error was used.
Testing Protocol. Generalization and substitution testing phases started immediately following discrimination training. On the first 4 consecutive days of a 5-day test cycle, rats had 2 nicotine and 2 saline training sessions intermixed as described earlier. On day 5, a 4-min test session occurred in place of a training session; no sucrose was available during this test session (Besheer et al., 2004; . Specifics regarding the ligands and order of testing are briefly detailed below and represented in Table 1 and Fig. 1 .
Nicotine Generalization. Across the 2 sets of rats, we determined 4 separate nicotine dose-effect curves. Three of the dose-effect curves used the testing protocol described earlier (see Table 1 and Fig. 1 for timing and doses) . Determination of the final nicotine dose-effect curve used a cumulative dosing regimen (Thompson et al., 1983) . In this regimen, rats were administered saline, then after the 5-min IPI, there was a 4-min sucrose-free test. Rats were removed from the chamber and given 0.025 mg/kg of nicotine. Following the IPI, there was another 4-min sucrose-free test. This procedure was repeated with 0.025 (0.05 cumulative dose), 0.05 (0.1), 0.1 (0.2), and finally 0.2 (0.4) mg/kg nicotine.
Ligand Substitution and Combination Tests. Substitution tests employed the same 5-day cycle described in the testing protocol section. On the 5th day of the cycle, the assigned ligand was administered at the prescribed IPI (Table 1 and Fig. 1 include the procedural details, doses, and order of testing). All doses were selected from previous studies (see Table 1 ). Testing combinations such as PNU-120596 plus nicotine was as described earlier, except on the test day there were two injections at the designated IPIs.
Dependent measures
For acquisition, we used dipper entry rate per second before the first sucrose delivery, or equivalent time during saline sessions. This measure avoids any influence of sucrose access in nicotine sessions on our measure of learning. For testing, we used the rate of dipper entries per second across the 4-min test session; recall that no sucrose occurred in these tests. We kept a rate measure so that the reader could compare the outcome of testing with acquisition. To measure general chamber activity, we used the number of center beam brakes throughout all the sessions.
Statistical analyses
To examine acquisition of drug discrimination responding (nicotine vs. saline), three-way ANOVAs were performed with Sex as a between-subjects factor and Drug and Session as withinsubjects factors. Significant interactions were followed by separate ANOVAs and LSD tests (see supplementary Table 2 ). Data from the substitution and generalization tests were analyzed using a multilevel approach. Multilevel modeling for repeated measures provides a number of advantages when compared to ANOVAs. For example, multilevel modeling does not assume that the relation between the covariate and the outcome is the same across the groups and thus does not require meeting the assumption of homogeneity. Furthermore, unlike ANOVA, multilevel modeling does not assume that the different cases of data were independent and hence can model relations between different outcomes which may be inter-related. Finally, multilevel modeling is more robust in dealing with missing data or unequal group sizes which is often the case in preclinical animal models.
With these advantages, dose-effect curves from substitution tests and generalization tests were analyzed by building a model with a maximum likelihood fit from a baseline that does not include any predictors other than an intercept. The model was built by first adding predictor 1 (Dose), then predictor 2 (Sex), then predictor 3 (Activity), and finally an interaction between predictor 1 and 2 (Dose Â Sex). The predictor or an interaction was declared significant when its addition improved the model by accounting for significantly more variance. The summaries of the model were used to estimate and report contrasts. Contrasts were restricted to control comparisons only (i.e., compared to 0 mg/kg control dose). Outcome of model comparisons and contrasts for each analysis are shown in Supplemental Table 3 through 5.
Results
discrimination training
Set 1. Recall Fig. 1 for the progression for each set of rats through the experiment. An omnibus ANOVA on acquisition training (see Fig. 2A ) revealed significant main effects of Drug and Session, as well as a significant Sex Â Drug and Sex Â Drug Â Session interactions (see Supplemental Table 2 for output of all omnibus ANOVAs). The significant Sex Â Drug Â Session interaction was followed by two-way Sex Â Session ANOVA, separately for nicotine and saline sessions. For nicotine sessions, there were significant main effects of Sex [
On average, male rats had overall higher responding than females. However, this difference dissipated by the end of the training (see sessions 15e19; Fig In sum, by the end of the acquisition phase, all rats reliably discriminated nicotine from saline and the magnitude of responding between female and males was similar.
Set 2. An omnibus ANOVA revealed significant main effects of Drug and Session, as well as significant Sex Â Session and Drug Â Session interactions (see Table 2 ); no other interactions were significant. The Sex Â Session interaction was not further investigated because a comparison that aggregates Drug (nicotine and saline) is not meaningful across sessions. Responding on the first nicotine session was lower than saline; this switched, with the nicotine stimulus evoking higher conditioned responding than saline for sessions 5 to 16 (LSD tests on combined means from females and males; Fig. 2B ; for consistency, data shown for females and males separately). The transient difference between females and males in Set 1 was not seen in Set 2 and is consistent with other Fig. 1 . A graphical representation of the testing order for each Set of rats used in this study. Table 3 ). There was no Dose Â Sex interaction. Contrasts revealed that 0.05, 0.1, 0.2, and 0.4 mg/kg nicotine evoked higher conditioned responding than saline (Fig. 3A) .
DEC-2. Conditioned responding significantly differed depending on the Dose [c 2 (4) ¼ 75.40, p < 0.0001], but not Sex or Activity.
There was no Dose Â Sex interaction. Contrasts revealed that 0.1 and 0.4 mg/kg nicotine evoked more conditioned responding than saline (Fig. 3B) . DEC-3. Conditioned responding significantly differed depending on the Dose [c 2 (4) ¼ 86.27, p < 0.0001], but not Sex or Activity.
There was no Dose Â Sex interaction. Contrasts revealed that 0.05, 0.1, and 0.4 mg/kg nicotine evoked more conditioned responding than saline (Fig. 3C) . Cumulative DEC. Responding using the cumulative dose-effect method resembled the pattern observed with the standard across session approach used to determine DEC-1 to 3. Conditioned responding significantly differed depending on the Dose [c 2 (4) ¼ 71.50, p < 0.0001]. The addition of the Sex factor to the model did not meet the criterion for significance (p ¼ 0.07). There was also no effect of Activity or Dose Â Sex interaction. Contrasts revealed that 0.1 and 0.4 mg/kg cumulative nicotine doses evoked greater conditioned responding than saline (Fig. 3D) . DECs comparison. To compare DECs (excluding 0.2 mg/kg dose from the DEC-1), the data from DEC-1 to 3 were aggregated and an Order factor with three levels for each DEC was appended to the data. There was no differences in conditioned responding between three determinations of the nicotine DEC (no effect of Order, p ¼ 0.42). In addition, there was no interaction with Order as a factor, nor a Dose Â Sex interaction. This outcome suggests relative stability of responding across experiments and time of determination.
Substitution for the nicotine stimulus
Sazetidine-A. Conditioned responding significantly differed depending on the Dose [c 2 (3) ¼ 56.48, p < 0.0001; for all analytical output in this section see Supplemental Table 4 ]. There was no effect of Sex or Activity, nor was there a Dose Â Sex interaction. Contrasts revealed that 1.0 and 3.0 mg/kg sazetidine-A evoked higher conditioned responding than saline (Fig. 4A) .
PHA. Conditioned responding significantly differed depending on the Dose [c 2 (3) ¼ 9.84, p < 0.05]. There was no effect of Sex or Activity, nor was there a Dose Â Sex interaction. Contrasts revealed that responding evoked by 3.0 mg/kg PHA was lower than saline ( Fig. 4B) . PNU. There was no effect of Dose,Sex, or Activity. There was no significant Dose Â Sex interaction. Neither dose of PNU evoked responding that differed from saline (Fig. 4C) .
Bupropion. Conditioned responding significantly differed depending on the Dose [c 2 (5) ¼ 14.73, p < 0.05]. There was no effect of Sex or Activity, nor was there a Dose Â Sex interaction.
Contrasts revealed that responding evoked by 10, 20, 30, and 60 mg/kg evoked greater conditioned responding than saline (Fig. 4D) .
Nornicotine. Conditioned responding significantly differed depending on the Dose [c 2 (4) ¼ 92.39, p < 0.0001]. There was no effect of Sex or Activity, nor was there a Dose Â Sex interaction. Contrasts revealed that responding evoked by 3.0 and 5.6 mg/kg was higher saline (Fig. 4E) (Fig. 4F) .
Overall comparison of ligands tested for substitution. To determine whether a compound partially or fully substituted for the nicotine stimulus, we compared responding evoked by the training dose of nicotine (0.4 mg/kg nicotine; DEC-1 to 3 combined) to the dose of each ligand that evoked the highest mean level of responding: 5.6 mg/kg nornicotine; 1.0 mg/kg sazetidine-A; 10 mg/kg bupropion; 1.0 mg/kg cytisine; 1.0 mg/kg PHA; 1.0 mg/kg of PNU. Because this comparison includes rats from both sets, we used a one-way GLM ANOVA with Drug as a between-subjects factor to analyze the data. There was a main effect of Drug [F(6, 118) ¼ 27.16, p < 0.0001]. Only nornicotine fully substituted for the nicotine stimulus as responding evoked by the 5.6 mg/kg dose did not differ from that evoked by nicotine ( Fig. 5 ; Tukey HSD tests). Sazetidine-A, bupropion, and cytisine partially substituted for the nicotine stimulus as responding evoked by each of these ligands was higher than saline (recall Fig. 4 ), but lower than that controlled by the training dose of nicotine ( Fig. 5 ; Tukey HSD tests). Responding evoked by PHA or PNU did not substitute for the nicotine stimulus as their responding was significantly lower than responding evoked by nicotine and that responding did not differ from responding evoked by saline in their respective substitution tests (Tukey HSD tests).
Combination tests
Sazetidine-A (1 mg/kg) þ Nicotine. Responding significantly differed depending on the Dose [c 2 (4) ¼ 16.25, p < 0.01; for all statistical output in this section see Supplemental Table 5 ]. There was no effect of Sex or Activity, nor was there a Dose Â Sex interaction. Contrasts revealed that responding evoked by a combination of 1 mg/kg of sazetidine-A and 0.05, 0.1, or 0.4 mg/kg of nicotine evoked higher conditioned responding than sazetidine-A alone (Fig. 6A) . Sazetidine-A (1 mg/kg) þ Bupropion. There was no effect of Sex, nor was there a Dose Â Sex interaction. Contrasts revealed that this combination did not enhance conditioned responding. Conversely, responding evoked by a combination of 1 mg/kg of sazetidine-A and 20, 30, or 60 mg/kg of bupropion evoked lower conditioned responding than sazetidine-A alone (Fig. 6B) . Because it appears that higher doses coincide with the decrease in goal-tracking responding, we conducted additional multivariate analyses investigating whether there was a Dose Â Activity interaction and whether there was difference in Activity between each bupropion dose and sazetidine-A alone (0 mg/kg bupropion dose; mean comparisons on Activity alone measure). We found that, although there was significant Dose Â Activity interaction [c 2
(1) ¼ 12.03, p ¼ 0.034], Activity alone at any dose from 5 to 60 mg/kg did not differ from 0 (sazetidine-A 1 mg/kg). Therefore, the decrease in goal-tracking at higher doses likely reflects the interaction of pharmacological stimulus effect and hyper-locomotor effects at 20 mg/kg dose or hypo-locomotor effects at 30 and 60 mg/kg (see point size representing activity in Fig. 6B ).
Sazetidine-A (1 mg/kg) þ Nornicotine. Responding significantly differed depending on the Dose [c 2 (4) ¼ 12.35, p < 0.05]. There was no effect of Sex or Activity, nor was there a Dose Â Sex interaction. Contrasts revealed that responding evoked by a combination of 1 mg/kg of sazetidine-A and 3 mg/kg of nornicotine was higher than sazetidine-A alone (Fig. 6C) . Sazetidine-A (1 mg/kg) þ Cytisine. There was no effect of Dose or Sex on responding. There was also no Dose Â Sex interaction. Although Dose comparisons did not reveal any significant differences (Fig. 6D) , addition of the Activity variable to the statistical model indicated a significant effect of Activity on responding [c 2 (1) ¼ 15.12, p < 0.001].
Nicotine (0.05 mg/kg) þ PNU. There was no effect of Dose or Sex on responding. There was also no Dose Â Sex interaction. Contrasts did not reveal any significant differences (Fig. 6E) .
Discussion
Since the publication of Bevins and Charntikov (2015) , there still remains not a single published paper that we can find that has nicotine as the training stimulus and investigates potential sex differences. Given this scientific gap, the main purpose of this study was to examine the nature of the nicotine stimulus in female and male rats using ligands selected for their action on nAChRs and/or their use in smoking cessation (recall Table 1 ). Overall, females and males acquired the discrimination between 0.4 mg/kg nicotine and saline at a similar rate. Further, the between session nicotine doseeffect curves were also comparable between sexes. Substitution and combination tests overall revealed similar patterns with the exception of cytisine. Cytisine evoked nicotine-like responding that was slightly, but significantly, higher for females. Although we did not discover any major differences between females and males, this study reflects an important step in understanding the nature of the nicotine stimulus in both sexes.
Nicotine primarily exerts its stimulus effects by activating (Besheer et al., 2004; Dwoskin et al., 2008; Struthers et al., 2009 ). In contrast, nAChR antagonists that do not readily cross the blood brain barrier (e.g., hexamethonium) do not affect responding to the nicotine stimulus (Besheer et al., 2004; Kumar et al., 1987) . The a4b2-containing nAChRs seem especially important for the stimulus effects of nicotine. nAChR agonists with varying specificity for the a4b2-containing receptors like TC-2559, ABT-594, ABT-418, and A-85380 evoke responding comparable to nicotine in substitution tests (Damaj et al., 1995; Goldberg et al., 1989; Jutkiewicz et al., 2011; Papke et al., 2007; Reichel et al., 2010) . Partial agonists for a4b2-containing nAChRs like varenicline and cytisine prompt partial to full substitution depending on the study (LeSage et al., 2009; Reichel et al., 2010; Smith et al., 2007) .
In the present study, we found that cytisine and sazetidine-A, both ligands with high affinity for the a4b2-containing receptors, met our definition of partial substitution for the nicotine stimulus. However, the mean level of responding evoked by the cytisine was less than half that of sazetidine-A, and less than a third of what was controlled by the training dose of nicotine (see Fig. 5 ). Sazetidine-A, is one of the promising drugs for the treatment of nicotine dependence. A conference abstract from the Society for Neuroscience is the only report known to us of sazetidine-A substitution for the nicotine stimulus (Xiao et al., 2007) . In vitro electrophysiological assays show that sazetidine-A potently evoked dopamine release from neurons expressing nAChRs (Zwart et al., 2008) ; this effect was blocked by dihydro-b-erythroidine and by mecamylamine. Because dopamine release from striatal slices is mediated by a4b2-and a6b2-containing receptors (Grady et al., 2007; Mogg et al., 2004; Salminen, 2004; Smith et al., 2007) , these electrophysiological findings suggest the involvement of these receptors. Furthermore, Zwart et al. (2008) found that the a6 nAChR selective antagonist a-CtxMII reduced striatal cell response evoked by sazetidine-A by approximately 48%. This effect indicated that sazetidine-A induced dopamine release was almost equally mediated by a4b2-and by a6-containing nAChRs. Along with some other promising preclinical reports (Johnson et al., 2012; Levin et al., 2010; Rezvani et al., 2010) , our findings further confirm the treatment potential of sazetidine-A. In contrast to the heteromeric nAChRs just discussed, the homomeric a7 nAChR does not seem to play a role in generation of the stimulus effects of nicotine. For example, a7 nAChR agonists GTS-21 and WO 01/60821A1 do not substitute for the nicotine stimulus (Smith et al., 2007; Stolerman et al., 2004) . Furthermore, pretreatment with the a7 nAChR antagonist GTS-21 or methyllycaconitine (MLA) does not alter responding controlled by the nicotine stimulus (Brioni et al., 1996; Van Haaren et al., 1999; Struthers et al., 2009; Zaniewska et al., 2006) . Corroborating and extending this past research, we found that neither PNU-120596, a positive allosteric modulator for the a7 nAChR, nor PHA-543613, a selective agonist for the a7 nAChRs, evoked nicotine-like responding (see later discussion). Previous studies report mixed findings with bupropion substitution for the nicotine stimulus: full substitution (Wiley et al., 2002; Wilkinson et al., 2009 Wilkinson et al., , 2010 Young and Glennon, 2002) ; partial substitution (Desai et al., 2003) ; no substitution (Shoaib et al., 2003) . At this point, unidentified procedural differences across studies are likely responsible for different outcomes. Our study adds partial substitution in females and males to this list. Recall that nicotine-like responding was highest at the 10, 20, 30, and 60 mg/kg doses of bupropion (see Fig. 4D ). Responding was somewhat lower and more variable at the higher doses (20e60 mg/ kg). A likely factor to be considered in this effect is bupropion evoked hyperlocomotion that has been previously well documented (Cooper et al., 1980; Nielsen et al., 1986; Wilkinson and Bevins and Caggiula, 2009; Wilkinson et al., 2006) . In fact, previous exposure to nicotine can enhance the subsequent locomotor stimulant effects of bupropion (Wilkinson et al., 2006) . However, our multivariate analysis does not show a significant contribution of the locomotor activity to the dose-dependent variability in our dependent measure e dipper entries. This outcome suggests that, at least in the experimental paradigm presented in this study, bupropion's locomotor effects do not interfere with its nicotine-like stimulus effects.
Nornicotine, is an alkaloid found in tobacco products, as well as a minor metabolite of nicotine in humans, non-human primates, and rodents (Benowitz, 1991; Ghosheh et al., 1999) . In the brain, nornicotine binds to various combinations of nAChR subunits among which it has highest affinity for a6/3b2b3, a7, and a4b2 Papke et al., 2007) . In the present study, we replicated past work showing that nornicotine (3.0 and 5.6 mg/kg) evoked nicotine-like responding in male rats (Desai et al., 1999; Goldberg et al., 1989; Reichel et al., 2010) and extended this observation to female rats. This substitution was comparable between sexes and at the highest dose tested (5.6 mg/kg), responding was statistically similar to the 0.4 mg/kg training dose of nicotine (i.e., full substitution). In fact, nornicotine was the only compound tested that fully substituted for the nicotine stimulus (see Fig. 5 ). Similar to substitution tests, combination tests can be used to elucidate receptor mechanisms contributing to the stimulus effects of nicotine. In the present study, findings from the substitution tests, along with the known pharmacological profiles of the ligands, guided our selection of drug interaction tests (recall Table 1 ). Because there is a limited understanding of the nicotine-like effects of sazetidine-A, we elected to perform a number of interaction tests with sazetidine-A and ligands with known nicotine-like stimulus effects. These types of tests are critical to start understanding receptor mechanism underlying sazetidine-A's substitution for the nicotine stimulus and further considering sazetidine-A as a possible therapeutic agent. To this end, we tested in females and males the effect of combining sazetidine-A with nicotine, bupropion, nornicotine, or cytisine. Notably, only combinations of 1 mg/kg sazetidine-A plus nicotine or nornicotine increased nicotine-like responding relative to sazetidine-A alone. Enhancement by the low dose of nicotine (0.05 mg/kg) likely reflects a summative action of the two compounds on a4b2-containing nAChRs. Importantly, we included the higher doses of nicotine (0.1e0.4 mg/kg) in the combination tests to determine if the partial agonist effect of sazetidine-A would decrease conditioned responding evoked by the nicotine stimulus. LeSage et al. (2009) found that the a4b2 partial agonist varenicline blunted responding to their training dose of nicotine. We, however, did not find a similar effect. Rather, these higher doses increased responding relative to sazetidine-A alone. Although the combination tests did not include a nicotine benchmark, examination of the nicotine dose-effect curves in the present study indicate that nicotine at 0.1 mg/kg or higher prompted responding comparable to the 0.4 mg/kg training dose. Future research will need to examine whether a higher dose of sazetidine-A can attenuate responding to these higher doses of nicotine.
The combination of 3 mg/kg nornicotine with sazetidine-A Significance: *p < 0.05, **p < 0.01, ***p < 0.001.
enhanced nicotine-like responding above that controlled by sazetidine-A alone. This effect was not seen at the higher dose of nornicotine (5.6 mg/kg) that prompted full substitution for nicotine when tested alone. Perhaps this decrease with 5.6 mg/kg nornicotine in the combination reflects partial antagonism by sazetidine-A. Our enthusiasm for this possibility is diminished by the lack of such an effect when the training dose of nicotine was used in the interaction test. Alternatively, when two compounds are tested together, the combination my produce stimulus effects that are distinct from either of the two drugs alone. These distinct stimulus elements may differ sufficiently from the training dose of nicotine, thus reducing responding in the test. The present study was not designed to examine this possibility. Future research will be needed to parse out potential neuropharmacological mechanisms contributing to the reduction in nicotine-like responding with the sazetidine-A plus 5.6 mg/kg nornicotine combination. Indeed, a similar possibility may explain the loss of conditioned responding at the higher doses of bupropion in combination of sazetidine-A; see also earlier discussion regarding locomotor effects of bupropion. PNU-120596 is a selective positive allosteric modulator for the a7 nAChRs. As detailed earlier, PNU-120596 alone did not substitute for the nicotine stimulus. To determine if this lack of effect reflected insufficient ACh tone in key brain areas, we examined whether PNU-120596 would enhance partial generalization evoked by a low dose of nicotine (0.05 mg/kg). Enhancement of conditioned responding was not evident at either dose of PNU-120596 tested in combination with nicotine. This outcome is consist with the present work and published studies indicating that the a7 nAChR does not play a role in generating the nicotine stimulus (Brioni et al., 1996; Van Haaren et al., 1999; Struthers et al., 2009; Zaniewska et al., 2006) . Women on average take less time than men to become dependent, make fewer attempts to quit smoking, remain abstinent for less time, have a higher relapse rate, and show less benefit from nicotine replacement therapy (Okene, 1993; Perkins and Scott, 2008; Perkins, 2001; Schnoll et al., 2007) . Research from animals models often corroborate these effects providing support for the assertion that some sex differences are rooted in biology (Harrod et al., 2004; Torres and O'Dell, 2016) . As described in the Introduction and reviewed in Bevins and Charntikov (Bevins and Charntikov, 2015) , until now, there has not been a single published study that we could find that used nicotine as the training stimulus and explicitly investigated sex differences. Overall, female rats, like their male counterparts, readily learn a discrimination between nicotine and saline, display a dose-dependent nicotine generalization curve, show substitution patterns as expected from published studies, and, importantly, do not show excessive variability as lab lore might suggest (cf. Prendergast et al., 2014) . Clearly much more research is needed in this area and the present research provides investigators with a strong beginning regarding the nature of the nicotine stimulus and the import of sex as a biological variable.
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